A trial looking at immunotherapy and combretastatin for advanced bowel and pancreatic cancer (A5B7-CA4P PH1/092)

Cancer type:

Bowel (colorectal) cancer
Pancreatic cancer




Phase 1

This trial was looking at combination of I-A5B7 and combretastatin (CA4P) for advanced bowel cancer and pancreatic cancer. This trial was supported by Cancer Research UK.

A5B7 is a type of biological therapy called a monoclonal antibody. Monoclonal antibodies target specific cells, and A5B7 targets cells that produce CEA Open a glossary item. This is a chemical produced by some cancer cells.

In this trial, the A5B7 had radioactive iodine attached to it, so it is called I-A5B7. The idea is that the radioactive iodine kills the cancer cells.

Combretastatin damages the blood vessels in the cancer. So it blocks the cancer’s blood supply and hopefully stops the cancer growing.

The aims of this trial were to find out

  • What effect I-A5B7 and combretastatin had on blood flow to the cancer
  • The best dose to give
  • More about the side effects
  • If I-A5B7 and combretastatin may be a useful treatment for cancer

Summary of results

This trial showed that the combination of I-A5B7 and combretastatin did change blood flow to the cancer. But even at low doses it caused serious side effects.

This trial was designed as a dose escalation study. That means that the first few people taking part have the lowest dose. The next few people have a higher dose. And so on, until the trial team find the best dose to give. But the people having the lowest dose had serious side effects, so the research team didn’t give anyone a higher dose.

The trial recruited 12 patients. Two people completed 1 cycle of treatment. But 10 people stopped treatment during the first cycle. This was usually because their cancer continued to grow and they were too unwell to have treatment.

The trial team looked at the scan results for 10 of the people who took part. They showed the cancer had stayed the same in 3 people (this is called ‘stable disease’). And it had continued to grow in 7 people.

The most common side effects were

  • A drop in blood cells causing an increased risk of infection, bleeding problems, tiredness and shortness of breath
  • Mild allergic reaction
  • Fast or slow pulse rate
  • High or low blood pressure

The research team concluded that the combination of A5B7 and combretastatin did change the flow of blood to cancer. But they had been unable to find the best dose to give because of the side effects of even a low dose. They recommended that it would be best to look at different combinations of treatments in future trials.

We have based this summary on information from the team who ran the trial. As far as we are aware, the information they sent us has not been reviewed independently (peer reviewed Open a glossary item) or published in a medical journal yet. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor RHJ Begent

Supported by

Cancer Research UK (Centre for Drug Development)
Experimental Cancer Medicine Centre (ECMC)

Cancer Research UK trial number

This is Cancer Research UK trial number CRUKD/03/037.

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle - 221

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Wendy took part in a new trial studying the possible side effect of hearing loss

A picture of Wendy

"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page